Redox Properties and in Vivo Magnetic Resonance Imaging of Cyclodextrin-Polynitroxides Contrast Agents |
| |
Authors: | Prof Lorenzo Franco Prof Abdirisak Ahmed Isse Prof Antonio Barbon Prof Lina Altomare MSc Viivi Hyppönen Dr Jessica Rosa Dr Venla Olsson Prof Mikko Kettunen Prof Lucio Melone |
| |
Institution: | 1. Department of Chemical Sciences, University of Padova, Via Marzolo 1, 35131 Padova, Italy;2. Department of Chemistry, Materials and Chemical Engineering “G.Natta”, Politecnico di Milano, Via Mancinelli 7, 20131 Milano, Italy;3. Metabolic MR Imaging, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Neulaniementie 2, 70211 Kuopio, Finland;4. Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Neulaniementie 2, 70211 Kuopio, Finland
Contribution: ?Investigation (supporting) |
| |
Abstract: | This paper reports the synthesis, characterization and in vivo application of water-soluble supramolecular contrast agents (Mw: 5–5.6 kDa) for MRI obtained from β-cyclodextrin functionalized with different kinds of nitroxide radicals, both with piperidine structure ( CD2 and CD3 ) and with pyrrolidine structure ( CD4 and CD5 ). As to the stability of the radicals in presence of ascorbic acid, CD4 and CD5 have low second order kinetic constants (≤0.05 M?1 s?1) compared to CD2 (3.5 M?1 s?1) and CD3 (0.73 M?1 s?1). Relaxivity (r1) measurements on compounds CD3 - CD5 were carried out at different magnetic field strength (0.7, 3, 7 and 9.4 T). At 0.7 T, r1 values comprised between 1.5 mM?1 s?1 and 1.9 mM?1 s?1 were found while a significant reduction was observed at higher fields (r1≈0.6-0.9 mM?1 s?1 at 9.4 T). Tests in vitro on HEK293 human embryonic kidney cells, L929 mouse fibroblasts and U87 glioblastoma cells indicated that all compounds were non-cytotoxic at concentrations below 1 μmol mL?1. MRI in vivo was carried out at 9.4 T on glioma-bearing rats using the compounds CD3 - CD5 . The experiments showed a good lowering of T1 relaxation in tumor with a retention of the contrast for at least 60 mins confirming improved stability also in vivo conditions. |
| |
Keywords: | cyclodextrin contrast agents glioma MRI imaging nitroxides |
|
|